Clinical Trial Update: Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update on the combination of ipilimumab and decitabine in patients with relapsed or refractory myelodysplastic syndromes or acute myeloid…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Dacogen (decitabine)
• ipilimumab (ipilimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-01-07